Gastrointestinal Cancer | Specialty

The Molecular-Driven Classification of Gastric Cancers

December 22nd 2017

Classification Guidelines for Gastric/GEJ Cancers

December 22nd 2017

Dr. Crane Discusses Radiation in Gastrointestinal Malignancies

December 21st 2017

Christopher Crane, MD, vice chair, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, discusses the role of radiation in the treatment of gastrointestinal malignancies.

Checkpoint Inhibitors, TKIs, and Novel Agents Poised to Enter Liver Cancer Treatment Paradigm

December 19th 2017

Ghassan K. Abou-Alfa, MD, discusses what he sees coming down the pike in epatocellular carcinoma with regard to novel agents, including CAR T-cell therapy, and the burgeoning questions with optimal sequencing of these treatments.

Questions Remain on Optimal mCRC Treatment

December 19th 2017

Leonard Saltz, MD, discusses current go-to therapies and overarching questions for mCRC treatment.

Surgery a Mainstay in Colorectal Cancer Treatment

December 19th 2017

William R. Jarnagin, MD, discusses the necessary role of surgery and novel techniques in patients with colorectal cancer.

CHMP Issues Positive Opinion on Herzuma for HER2+ Breast, Gastric Cancers

December 19th 2017

The European Union’s CHMP has delivered a positive opinion for Herzuma (CT-P6), a trastuzumab (Herceptin) biosimilar in HER2-positive early breast cancer, metastatic breast cancer, and metastatic gastric cancer.

Dr. Bendell Discusses Pembrolizumab in CRC

December 19th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Dr. O'Reilly Discusses Advancements in Early-Stage Pancreatic Cancer

December 16th 2017

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses advances for patients with early stage pancreatic cancer.

Pembrolizumab Misses Endpoints in Phase III Gastric Cancer Trial

December 15th 2017

Pembrolizumab did not improve survival as a second-line treatment for PD-L1–positive patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from the phase III KEYNOTE-061 trial.

Dr. Kemeny on Liver-Directed Therapy for Metastatic CRC

December 14th 2017

Nancy E. Kemeny, MD, a medical oncologist at Memorial Sloan Kettering Cancer Institute, discusses liver-directed therapies for patients with metastatic colorectal cancer (CRC).

Expert Says Clinical Trials Are Essential for Progress in Metastatic CRC

December 13th 2017

Shubham Pant, MD, stresses the importance of clinical trials as an avenue to establish more novel treatment decisions in colorectal cancer.

Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI Cancer

December 13th 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.

Solving the BRAF Mystery in CRC: Genomic Clues Lead to Triplets and Immunotherapy

December 13th 2017

Mutations in the BRAF kinase are found in a relatively small number of patients with metastatic colorectal cancer, but they nonetheless have important implications for prognosis and response to standard therapy.

Dr. Saltz Discusses Chemotherapy in Metastatic CRC

December 12th 2017

Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.

Experts Describe Challenges of Targeting BRAF Mutations in CRC

December 12th 2017

Tanios Bekaii-Saab, MD, FACP, and Rona D. Yaeger, MD, discuss the current treatment landscape and other key issues relating to this distinct subset of colorectal cancer.

Frontline Ramucirumab Does Not Improve OS in Gastric Cancer

December 9th 2017

Adding ramucirumab to cisplatin and capecitabine or 5-FU in the frontline setting did not improve overall survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, according to topline results from the phase III RAINFALL trial.

Dr. Pant on the Third-Line Setting for Metastatic CRC

December 6th 2017

Shubham Pant, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the third-line setting for patients with metastatic colorectal cancer (CRC).

Dr. Pishvaian Discusses Progress in Pancreatic Cancer

December 5th 2017

Michael Pishvaian, MD, PhD, discusses the progress that has been made in the treatment of patients with pancreatic cancer during the 2017 Ruesch Center Symposium.

Dr. Marshall Discusses the State of RAS Mutations in GI Cancers

December 5th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses the current state of RAS-mutant gastrointestinal (GI) cancers during the 2017 Ruesch Center Symposium.